2020
DOI: 10.1002/jmv.25964
|View full text |Cite
|
Sign up to set email alerts
|

Tocilizumab for the treatment of severe coronavirus disease 2019

Abstract: Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidn… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

16
253
1
8

Year Published

2020
2020
2020
2020

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 237 publications
(285 citation statements)
references
References 22 publications
16
253
1
8
Order By: Relevance
“…Meta-regression scatter plot representing the correlation between BMI and IMV is shown in Figure S2. 15,[28][29][30][31][32][33][34] No correlation was found F I G U R E 2 Odds ratios for intensive care unit admission in patients with obesity versus patients without obesity. BMI, body mass index; CI, confidence interval; ICU, intensive care unit F I G U R E 3 Odds ratios for invasive mechanical ventilation (IMV) in patients with obesity versus patients without obesity.…”
Section: Meta-regressionmentioning
confidence: 98%
“…Meta-regression scatter plot representing the correlation between BMI and IMV is shown in Figure S2. 15,[28][29][30][31][32][33][34] No correlation was found F I G U R E 2 Odds ratios for intensive care unit admission in patients with obesity versus patients without obesity. BMI, body mass index; CI, confidence interval; ICU, intensive care unit F I G U R E 3 Odds ratios for invasive mechanical ventilation (IMV) in patients with obesity versus patients without obesity.…”
Section: Meta-regressionmentioning
confidence: 98%
“…Early reports show that tocilizumab, an IL-6 inhibitor, may be beneficial in this patient population. [40][41][42] Furthermore, due to the observed alterations at the arterial, venous, and atrial endothelium further studies are warranted to assess the optimal anticoagulative strategy including different anticoagulants and potential combinations of anticoagulants with antiplatelet drugs.…”
Section: Novel Therapeutic Approaches In Covid-19mentioning
confidence: 99%
“…In a single centre study from Wuhan including 15 patients TOCI appeared to be an effective treatment option in patients with cytokine storm [13]. In a retrospective analysis of 25 unmatched ICU patients, TOCI at the median dose of 5,7 mg/Kg showed a signi cant reduction in invasive mechanical ventilation at day 14, although 90% of patients showed adverse events [26]. A prospective multi-centre safety study on 66 patients reported no moderate to severe adverse events related to TOCI with a signi cant improvement in PaO2/FiO2 ratio, ferritin, C-reactive protein, D-dimer and lymphocytes count at day 14 [27].…”
Section: Discussionmentioning
confidence: 98%